JI LIN AO DONG released its performance for the first half of the year, with a net profit attributable to the parent company of 1.282 billion yuan, an increase of 138.44%

According to the Zhitong Finance APP, JI LIN AO DONG (000623.SZ) released its semi-annual report for 2025, showing an operating income of 1.126 billion yuan, a year-on-year decrease of 20.21%. The net profit attributable to shareholders of the listed company was 1.282 billion yuan, a year-on-year increase of 138.44%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.167 billion yuan, a year-on-year increase of 43.68%. The basic earnings per share were 1.0915 yuan. In addition, it plans to distribute a cash dividend of 2.00 yuan (including tax) for every 10 shares to all shareholders.

During the reporting period, the pharmaceutical and chain pharmacy wholesale and retail business achieved an income of 1.016 billion yuan, accounting for 90.22% of the operating income, a decrease of 16.31% compared to the same period last year. Among them, the operating income of traditional Chinese medicine was 686 million yuan, a decrease of 21.41% compared to the same period last year; the operating income of chemical drugs was 143 million yuan, a decrease of 6.02% compared to the same period last year; the operating income of chain pharmacy wholesale and retail business was 187 million yuan, a decrease of 1.07% compared to the same period last year